{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-045227","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2025-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.212487+00:00","generated_at":"2026-05-24T05:21:11.210900+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Perspective Therapeutics reports FY2024 net loss $79.3M; cash $227M; VMT-α-NET enrollment reaches 30 patients","bullets":["Net loss of $79.3M ($1.23 loss per share) vs $46.5M in FY2023; R&D spend doubled to $41.6M.","Goodwill impairment of $24.1M due to low market cap; cash and investments $227M, funding expected into late 2026.","VMT-α-NET Phase 1/2a enrolled 30 patients in Cohort 2 as of Feb 2025; no DLTs, one confirmed response.","IND cleared for PSV359 (FAP-α targeting); first patient dosing expected mid-2025.","In Feb 2025, sold 3.38M shares under ATM at ~$3.02 for gross proceeds of $10.2M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-045227","json":"https://secwatch.observer/filing/0000950170-25-045227.json","markdown":"https://secwatch.observer/filing/0000950170-25-045227.md","text":"https://secwatch.observer/filing/0000950170-25-045227.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000095017025045227/0000950170-25-045227-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000095017025045227/catx-20250326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T05:21:11.210900+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}